Home › NCT07195032

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Who can join

Ages 1 to 17 · All sexes

Inclusion Criteria:

* Received a heart transplant
* At least 1 year after transplant
* At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
* At least 1 year from anti-thymocyte globulin
* At least 6 months after pulse dose steroid treatment or basiliximab treatment
* No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion
* Clinically well

Exclusion Criteria:

* History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.
* History of anaphylactic reaction to MMR vaccination

About the study

The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.

What is being tested

• Commercial measles, mumps, and rubella (MMR) vaccine (drug)

Sponsor: Children's Mercy Hospital Kansas City · Participants: 60 · Started: Sep 11, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07195032

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.